Revolution Medicines (RVMD) Retained Earnings (2019 - 2026)
Revolution Medicines' quarterly Retained Earnings came in at -$622000.0 in Q1 2026, up 99.97% year-on-year from -$311048.4 in Q1 2025, and up 99.98% quarter-over-quarter from -$2.9 billion in Q4 2025.
Revolution Medicines has reported Retained Earnings for 8 years, with the latest figure at -$622000.0 in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings rose 99.97% year-over-year to -$622000.0; the trailing twelve-month figure through Mar 2026 stood at -$622000.0 (up 99.97% YoY), and the FY2025 full-year result was -$2.9 billion, down 65.1% from the prior year.
- Retained Earnings for Q1 2026 stood at -$622000.0, up from -$2.9 billion in the prior quarter.
- The five-year high for Retained Earnings was $3.8 million in Q3 2024, with the low at -$2.9 billion in Q4 2025.
- Average Retained Earnings over 5 years is -$1.1 billion, with a median of -$867.7 million recorded in 2023.
- Year-over-year, Retained Earnings slumped 6350100.0% in 2022 and jumped 537.66% in 2024.
- Tracing RVMD's Retained Earnings over 5 years: stood at -$701.3 million in 2022, then tumbled by 62.22% to -$1.1 billion in 2023, then slumped by 52.75% to -$1.7 billion in 2024, then plunged by 65.1% to -$2.9 billion in 2025, then surged by 99.98% to -$622000.0 in 2026.
- The last three Retained Earnings figures came in at -$622000.0 (Q1 2026), -$2.9 billion (Q4 2025), and -$2.5 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | -622,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -622,000.00 |
| Dec 31, 2025 | -2.87 Bn |
| Sep 30, 2025 | -2.50 Bn |
| Jun 30, 2025 | -2.20 Bn |
| Mar 31, 2025 | -2.00 Bn |
| Dec 31, 2024 | -1.74 Bn |
| Sep 30, 2024 | 3.81 Mn |
| Jun 30, 2024 | -1.39 Bn |
| Mar 31, 2024 | -1.25 Bn |
| Dec 31, 2023 | -1.14 Bn |
| Sep 30, 2023 | -871,000.00 |
| Jun 30, 2023 | -867.70 Mn |
| Mar 31, 2023 | -769.44 Mn |
| Dec 31, 2022 | -701.34 Mn |
| Sep 30, 2022 | -644.83 Mn |
| Jun 30, 2022 | -571.50 Mn |
| Mar 31, 2022 | -510.30 Mn |
| Dec 31, 2021 | -452.64 Mn |
| Sep 30, 2021 | -40,000.00 |
| Jun 30, 2021 | 9,000.00 |
| Mar 31, 2021 | -302.72 Mn |
| Dec 31, 2020 | -265.55 Mn |
| Sep 30, 2020 | -231.34 Mn |
| Jun 30, 2020 | -204.12 Mn |
| Mar 31, 2020 | -176.91 Mn |
| Dec 31, 2019 | -157.39 Mn |